Janesville-based SHINE Medical Technologies LLC has closed $80 million in Series C financing supported by Fidelity Management and Research Company LLC, according to a release from the company.
The nuclear technology company’s latest and largest financing round included participation from Fidelity, other new investors, and the company’s current investors. SHINE continues to make progress in commercializing molybdenum-99, an essential diagnostic isotope, and lutetium-177, a therapeutic isotope that is showing great promise for the treatment of cancer.
